The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of StemPrintER, a novel biology-based genomic predictor of distant recurrence in breast cancer, with Oncotype DX in the TransATAC cohort.
 
Salvatore Pece
Patents, Royalties, Other Intellectual Property - • Cancer Marker Patent US 7901876 (B2)/WO2006037462 (A3)/EP1802971 - Cancer Biomarkers,”Methods of diagnosis and prognosis, including E1A-induced genes and Numb; • Pending Patent EP/20.06.16/EPA16175354 “Methods and Kits comprising gene signatures for stratifying breast cancer patients”
 
Ivana Sestak
Honoraria - Myriad Genetics; NanoString Technologies; Pfizer
Consulting or Advisory Role - Myriad Genetics
 
Francesca Montani
No Relationships to Disclose
 
Micol Tillhon
No Relationships to Disclose
 
Stefano Freddi
No Relationships to Disclose
 
Patrick Maisonneuve
No Relationships to Disclose
 
Marco Colleoni
Honoraria - Novartis
 
Paolo Veronesi
No Relationships to Disclose
 
Davide Disalvatore
No Relationships to Disclose
 
Giuseppe Viale
Honoraria - MSD Oncology; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer; Daiichi Sankyo; Dako; Menarini; MSD Oncology; Novartis; Roche/Genentech
Speakers' Bureau - Roche/Genentech
Research Funding - Cepheid (Inst); Dako/Agilent Technologies (Inst); Roche/Genentech; Ventana Medical Systems (Inst)
Travel, Accommodations, Expenses - Celgene; Roche
 
Richard Buus
No Relationships to Disclose
 
Jack M. Cuzick
Honoraria - Merck; Qiagen; Roche
Consulting or Advisory Role - Merck; Myriad Genetics; Qiagen; Roche
Speakers' Bureau - Becton Dickinson
Research Funding - AstraZeneca (Inst); Aventis Pharma (Inst); Becton Dickinson (Inst); GeneFirst (Inst); Genera Biosystems (Inst); Myriad Genetics (Inst); Qiagen (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Myriad Geneticsto institution of which I receive a share for development of Cell cycle progression score (Prolaris)
Travel, Accommodations, Expenses - GE Healthcare
 
Mitchell Dowsett
Honoraria - Myriad Genetics
Consulting or Advisory Role - G1 Therapeutics; GTx; Orion; Radius Health; Radius Health
Research Funding - Pfizer (Inst); Radius Health (Inst)
Travel, Accommodations, Expenses - Myriad Genetics; Pfizer
Other Relationship - Institute of Cancer Research
 
Pier Paolo Di Fiore
Stock and Other Ownership Interests - Genextra
Patents, Royalties, Other Intellectual Property - • Cancer Marker Patent US 7901876 (B2)/WO2006037462 (A3)/EP1802971 - Cancer Biomarkers,”Methods of diagnosis and prognosis, including E1A-induced genes and Numb; • Pending Patent EP/20.06.16/EPA16175354 “Methods and Kits comprising gene signatures for stratifying breast cancer patients